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Pertussis (also known as whooping cough) 
is a highly contagious disease mainly caused by 
the bacterium Bordetella pertussis. It is a strictly 
human disease and affects all ages.1 However, the 
morbidity and mortality associated with pertussis are 
disproportionally high in young infants — the age 
group in which we observe virtually all hospitalizations, 
complications, and deaths related to pertussis.2-4
There is strong evidence in the literature showing 
that the severity of pertussis in these young infants 
is related to the production of toxins by B. pertussis, 
particularly pertussis toxin (PT). PT has a critical role in the 
pathogenesis of severe disease; it induces leukocytosis 
with lymphocytosis and elevated cAMP levels, which 
contribute to pulmonary vasoconstriction. Extreme 
leukocytosis is a marker of poor outcome in young 
infants with pertussis, and is frequently associated 
with severe hypoxemia, pulmonary hypertension, and 
death.5,6
The introduction of routine immunization 
programs against pertussis in children worldwide 
provided a substantial reduction in the incidence of 
the disease. However, control of the disease has never 
been achieved, and in the last decade a resurgence of 
pertussis was reported in several countries.7,8 Although 
the reasons for this resurgence are not fully understood, 
the probable factors that explain the observed increased 
rates of disease worldwide are: (i) the availability of 
more sensitive techniques (polymerase chain reaction) 
for the diagnosis; (ii) increased awareness and 
more efficient reporting among healthcare workers; 
(iii) genetic changes in B. pertussis strains; and (iv) rapid 
waning immunity after acellular vaccines.9
The rapidly waning immunity, which occurs 
after either immunization or natural exposure to 
the causative agent, plays a critical role in disease 
transmission in the community. Several studies 
confirmed the importance of household contacts as the 
main source of pertussis transmission to unprotected 
young infants.10-12 The absence of the classic pertussis 
symptoms in most of the infected adolescents and 
adults makes the recognition of the disease and the 
diagnosis difficult in this age group.
In order to anticipate protection against pertussis, 
the strategy of using pertussis vaccines during the 
newborn period has been attempted in several studies. 
Despite conflicting results, there was a trend toward 
lower responses to subsequent vaccine doses, either 
using whole-cell or acellular vaccines, which limited 
the utility of this approach.13
In an effort to provide indirect protection to 
vulnerable young infants, different vaccination 
strategies targeting adolescents and adults – in 
addition to children – were recommended in several 
countries, including vaccination programs with Tdap 
(tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis) for adolescents, adults, postpartum 
women, and household contacts of infants.14,15
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The implementation of adolescent programs with 
a single Tdap dose in the US resulted in a decrease in 
the incidence rates of disease among the age group 
targeted for the vaccination. However, the expected 
indirect effects of adolescent Tdap vaccination were 
not observed in other unvaccinated age groups, 
including infants.16 The limited role that adolescents 
play in the transmission of disease to infants, the low 
coverage of vaccination programs among adolescents, 
and the limitations of the Tdap vaccine to protect 
against pertussis infection, were implicated in the lack 
of impact of this strategy on disease rates in young 
infants. Another intervention that was implemented 
with the aim of providing indirect protection to young 
infants was the “cocooning” strategy: the vaccination 
of postpartum women, plus adolescents and adults who 
have close contact with infants (including healthcare 
workers). Although parents and other caregivers of 
infants have been shown to be an important source of 
disease transmission to young infants, this strategy also 
proved to be of limited impact in the real world setting. 
The major challenge for the “cocoon” strategy is to 
achieve broad vaccination coverage among all potential 
close contacts of the newborn infant. Immunization of 
only postpartum mothers with the Tdap vaccine was 
demonstrated to be insufficient to reduce pertussis 
illness in infants ≤ 6 months of age.17
The persistent high rates of pertussis, which 
are associated with the unacceptably high morbidity 
and mortality observed in young infants (despite all 
the efforts to control the disease in this vulnerable 
age group) led the health authorities in several 
countries to recommend an alternative approach: the 
implementation of maternal vaccination programs 
for pertussis during pregnancy.18,19 The rationale of 
this strategy is to provide protection for infants from 
birth through the trans-placental passive transfer 
of maternal antibodies. This strategy has the added 
benefit of protecting the mother against disease, 
potentially reducing household transmission, and 
preventing infant infection.
In order to optimize antibody transfer and 
protection at birth, taking into account the results from 
antibody kinetics studies performed in healthy adults,20 
the recommendation is to vaccinate women between 
28 and 38 weeks of gestation.19 The short persistence 
of anti-pertussis antibodies in women previously 
vaccinated emphasizes the need to recommend a Tdap 
dose in each pregnancy.21
A few years after being implemented, the 
recent publication of data on the uptake, safety, and 
effectiveness of the pertussis vaccination program for 
pregnant women in the UK, as well as the impact on 
disease rates in infants, is encouraging and provides 
robust evidence in favor of this intervention.22-27
The results of the first two studies evaluating the 
effectiveness of the program, using different methods, 
have each shown for the very first time that maternal 
immunization with an acellular pertussis vaccine 
provided around 90% protection against disease in 
young infants.25,26
By December 2014 in the UK, more than 60% of 
pregnant women received a dose of the pertussis 
vaccine—the highest rate since the start of the program 
in October 2012. The reduction in disease rates has 
been observed in infants under 6 months of age who 
are targeted by the maternal pertussis vaccination 
program, without an impact on other age groups. After 
the introduction of the pregnancy program in the UK, 
10 deaths had been reported in young infants with 
confirmed pertussis, of which 9 were born to mothers 
who had not been vaccinated against pertussis.27
Furthermore, no evidence of an increased risk of 
adverse events among these women or their infants 
was reported in clinical trials, in observational cohort 
studies, or in post-marketing surveillance reports 
evaluating the safety of pertussis vaccines during the 
third trimester of pregnancy.22-24
In Brazil, the same phenomenon reported in other 
countries was also observed with increasing rates of 
cases, hospitalizations, and deaths related to pertussis 
in recent years. In 2013, 109 pertussis-related deaths 
were reported – a number 7-fold higher than the 
average number of deaths reported annually in the 
period from 2001 to 2010. More than 80% of the 
deaths occurred in infants younger than 3 months of 
age. To address this serious situation, in late 2014, 
the Ministry of Health announced the introduction of 
the Tdap vaccine for all pregnant women in Brazil.28 
Argentina, Uruguay, Costa Rica, Mexico, Panama, 
Israel, New Zealand, and Belgium – among other 
countries – also implemented maternal vaccination 
programs for pertussis during pregnancy, following 
the examples from the US and the UK.29
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Although continued surveillance is still needed 
to provide more robust evidence of the long-term 
safety and effectiveness of Tdap immunization 
programs during pregnancy, the early results of these 
programs are encouraging, which highlights the 
importance of educating healthcare providers and 
the public on the benefits of maternal immunization 
in order to achieve control of pertussis in young 
infants. The great challenge of this intervention 
appears to be the goal of a high coverage among 
the pregnant women cohort to optimize the impact 
of the vaccination program. All countries that can 
afford the costs of a Tdap vaccination program in 
pregnant women should not postpone the decision 
to implement these recommendations. It is time to 
vaccinate pregnant women!
Finally, maternal immunization during pregnancy 
also seems to be a very attractive strategy to control 
other diseases that are potentially preventable by 
vaccines. In the next coming years, the experience 
accumulated with tetanus, influenza, and pertussis 
will pave the way for the development of maternal 
vaccination programs against other severe diseases 
for the young infant, such as those caused by group 
B streptococcus and respiratory syncytial virus.
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